Her main research concerns Immunology, Atopic dermatitis, Allergy, Immune system and Atopy. Her Immunology study combines topics in areas such as Epithelium and Disease. Her study in the field of Eczema Area and Severity Index also crosses realms of Task force.
Her Eczema Area and Severity Index research is multidisciplinary, relying on both Placebo and Dupilumab. Her Immune system research is multidisciplinary, incorporating perspectives in Genetic enhancement and Granulocyte macrophage colony-stimulating factor. Her work carried out in the field of Atopy brings together such families of science as Filaggrin and Eczema herpeticum.
Her primary areas of study are Atopic dermatitis, Immunology, Dermatology, Dupilumab and Eczema herpeticum. Her Atopic dermatitis research focuses on Eczema Area and Severity Index in particular. Her research in Allergy, Eosinophil, Innate immune system, Atopy and Immune system are components of Immunology.
Her studies in Allergy integrate themes in fields like Family medicine, Immunoglobulin E, Asthma and Immunopathology. Lisa A. Beck integrates Dermatology with In patient in her research. Her work in Dupilumab tackles topics such as Clinical trial which are related to areas like Peanut allergy, Patient advocacy, Public health and Pediatrics.
Lisa A. Beck mainly investigates Atopic dermatitis, Dupilumab, Dermatology, Immunology and Internal medicine. Lisa A. Beck studies Atopic dermatitis, namely Eczema Area and Severity Index. Lisa A. Beck combines subjects such as Post-hoc analysis, Quality of life, Disease and Severe atopic dermatitis with her study of Dupilumab.
Her work on Adult atopic dermatitis as part of general Dermatology study is frequently connected to Baseline weight, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. Her Immunology research is multidisciplinary, incorporating elements of Barrier function, Colonization and Staphylococcus aureus. Lisa A. Beck has included themes like Food allergy and Transplantation in her Asthma study.
Lisa A. Beck mostly deals with Atopic dermatitis, Internal medicine, Dupilumab, Eczema Area and Severity Index and Placebo. Her research in Atopic dermatitis intersects with topics in SCORAD, Randomized controlled trial, Skin infection, Asthma and Food allergy. As a part of the same scientific study, she usually deals with the Skin infection, concentrating on Virulence and frequently concerns with Immunology.
Lisa A. Beck interconnects Human skin, Methylation and DNA methylation in the investigation of issues within Immunology. Her study on Food allergy also encompasses disciplines like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
Joshua A. Boyce;Amal Assa'ad;A. Wesley Burks;Stacie M. Jones.
The Journal of Allergy and Clinical Immunology (2011)
Cytokine modulation of atopic dermatitis filaggrin skin expression
Michael D. Howell;Byung Eui Kim;Peisong Gao;Audrey V. Grant.
The Journal of Allergy and Clinical Immunology (2007)
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham.
The New England Journal of Medicine (2014)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck.
The New England Journal of Medicine (2016)
Tight junction defects in patients with atopic dermatitis.
Anna De Benedetto;Nicholas M. Rafaels;Laura Y. McGirt;Andrei I. Ivanov.
The Journal of Allergy and Clinical Immunology (2011)
Activation of Airway Epithelial Cells by Toll-Like Receptor Agonists
Quan Sha;Ai Q. Truong-Tran;James R. Plitt;Lisa A. Beck.
American Journal of Respiratory Cell and Molecular Biology (2004)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber.
The Lancet (2016)
Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by ex Vivo Granulocyte-Macrophage Colony-stimulating Factor Gene Transfer
J.W. Simons;E.M. Jaffee;C.E. Weber;H.J. Levitsky.
Cancer Research (1997)
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Jennifer K Garrett;Sean C Jameson;Blythe Thomson;Margaret H Collins.
The Journal of Allergy and Clinical Immunology (2004)
Omalizumab-induced reductions in mast cell FcεRI expression and function
Lisa A. Beck;Gregory V. Marcotte;Donald MacGlashan;Alkis Togias.
The Journal of Allergy and Clinical Immunology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Boston Children's Hospital
Oregon Health & Science University
University of Colorado Anschutz Medical Campus
National Jewish Health
University of Colorado Denver
University of California, San Diego
Northwestern University
Johns Hopkins University
Icahn School of Medicine at Mount Sinai
University of California, San Diego
TU Darmstadt
University of Toronto
University of Southampton
Texas A&M University
Philipp University of Marburg
University of Cologne
University of California, Riverside
University of Genoa
Boston Children's Hospital
United States Geological Survey
Centre national de la recherche scientifique, CNRS
University of Barcelona
Rockefeller University
Medical University of South Carolina
Clark University
University of Minnesota